

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/300,612	04/27/1999	BINIE V. LIPPS	FWLPATU012	4662	
7590 09/08/2004		EXAMINER			
JOHN R CASPERSON P O BOX 2174			BASKAR, PADMAVATHI		
FRIENDSWOO	DD, TX 77549		ART UNIT	PAPER NUMBER	
			1645		
			DATE MAILED, 00/09/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

`	Application No.	Applicant(s)
	09/300,612	LIPPS ET AL.
Office Action Summary	Examiner	Art Unit
	Padmavathi v Baskar	1645
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1)⊠ Responsive to communication(s) filed on 17 Ju	ine 2004.	
	action is non-final.	
3) Since this application is in condition for allowar closed in accordance with the practice under E	•	
Disposition of Claims		
4) ⊠ Claim(s) <u>5,7-10,15 and 16</u> is/are pending in the 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>5,7-10,15 and 16</u> is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	vn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the conference of Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine 11).	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)	_	
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 		(PTO-413) te. <u>3/25,31,4/8,6/15/0,2</u> atent Application (PTO-152)

Application/Control Number: 09/300,612 Page 2

Art Unit: 1645

Amendment

1. The amendments filed on 10/20/03, 1/07/04, 4/08/04 and 6/17/04 have been entered into the record.

Status of Claims

2. Claims 5 and 7-19 are pending in the application.

Claims 5, 7-10, 15-16 have been amended.

Claims 11-14, 17 and 18, 19 have been cancelled.

Claims 5, 7-10 and 15-16 are currently under examination.

Objection Withdrawn

3. In view of amendment to the claims and cancelation of claim 14, the objection of claims, 5, 9, 11 and 14 is withdrawn.

Rejections Withdrawn/moot

- 4. In view of amendment to the claims and cancellation of claims, the rejection of claims 5, 7-10, 15-16 under 35 U.S.C. 112, second paragraph is withdrawn.
- 5. In view of cancellation of claims, the rejection of claims 11- 13 under 35 U.S.C. 102(b) as being anticipated by Sanchez et al 1998 (Toxicon: 36: 1451- 1459 in light of Farah et al 1996, Toxicon: 34: 1067- 1071) is moot.
- 6. In view of amendment to the claims and cancellation of claims 14, the rejection of claims 5, 7-8 and 15-16 under 35 U.S.C. 103(a) as being unpatentable over Sanchez et al (Toxicon: 36: 1451- 1459 in view of Harlow and Lane 1988) is withdrawn.

Claim Rejections - 35 USC § 112

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to

Application/Control Number: 09/300,612

Art Unit: 1645

enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 5, 7-10 and15-16 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a process for detecting a toxin or free toxin in a biological sample, said process comprising (a) contacting a biological sample with antibodles raised against a synthetic peptide consisting of SEQ ID NO: 1 or synthetic peptide LTNF -10 (peptide consisting of first 10 amino acids SEQ.ID.NO: 1) or against a natural 68 kDa Lethal Toxin Neutralizing Factor protein said protein is isolated from opossum serum (b) detecting the immune complex formed between the toxin and the antibodies by ELISA, does not reasonably provide enablement for a process for detecting a toxin or free toxin in a biological sample, said process comprising (a) contacting a biological sample with antibodies raised against at least five amino acids of SEQ.ID.NO: 1 (viewed as any random five amino acids of SEQ.ID.NO: 1) (b) detecting the immune complex formed between the toxin and the antibodies by ELISA. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The claims are drawn to a process for detecting a toxin or free toxin in a biological sample, said process comprising (a) contacting a biological sample with antibodies raised against a synthetic peptide consisting of at least five amino acids of SEQ ID NO: 1, or against a natural 68 kDa Lethal Toxin Neutralizing Factor protein, said protein is isolated from opossum serum (b) detecting the immune complex formed between the toxin and the antibodies by ELISA.

The specification teaches only a process for detecting a toxin or free toxin in a biological sample, said process comprising (a) contacting a biological sample with antibodies raised against a synthetic peptide SEQ ID NO: 1, or synthetic peptide LTNF-10 consisting of first ten

Application/Control Number: 09/300,612

Art Unit: 1645

amino acids of SEQ.ID.NO: 1 or against a natural 68 kDa Lethal Toxin Neutralizing Factor protein, said protein is isolated from opossum serum (b) detecting the immune complex formed between the toxin and the antibodies by ELISA. The specification is silent concerning, a process for detecting a toxin or free toxin in a biological sample, said process comprising (a) contacting a biological sample with antibodies raised against at least five amino acids of SEQ.ID.NO: 1(viewed as any random five amino acids of SEQ.ID.NO: 1) (b) detecting the immune complex formed between the toxin and the antibodies by ELISA.

The specification and the state of art (U.S.Patent 5,744,449) indicate that the antibodies raised against antigen LTNF-n, LTNF-15 and LTNF-10 bind to LTNF-n, LTNF-15 and LTNF-10 and to the toxin obtained from various biological samples (see the table below from (U.S.Patent 5,744,449)

TABLE VIII

Binding Affinity of Venoms and Toxins to Anti LTNF-n and LTNF-s by ELISA

	ELISA Antibody Titer			
Antigen	LTNF-n	LTNF-15	LTNF-10	
LTNF-n	12800	12800	12800	
LTNF-15	800	1600	600	
LTNF-10	800	400	1600	
C. atrox venom	600	600	800	
N. n. Kaouthia venom	800	400	400	
R. viper venom	3200	1600	1600	
O scutellatus venom	300	600	600	
Scorpion venom	600	600	800	
Bee venom	7200	1600	1600	
Ricin	600	300	800	
Cobratoxin	1600	1600	3200	
Phospholipase (PhLA2) toxin	800	800	1600	
Taipoxin	1600	1600	3200	

Application/Control Number: 09/300,612

Art Unit: 1645

The specification in the present application teaches that antibodies to N terminal LTNF-10

detect the toxin and it is an active domain of LTNF-n. However, the specification fails to teach

antibodies to at least five amino acids of SEQ.ID.NO: 1 (viewed as any random five amino

acids of SEQ.ID.NO: 1) binds to toxin and thereby could detect free toxin or toxin in a biological

sample. Thus, the specification lacks support for the full scope of the invention as claimed.

Remarks

8. No claims are allowed.

9. Papers related to this application may be submitted to Group 1600, AU 1645 by

facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives

transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile

must conform with the notice published in the Official Gazette, 1096 OG 30, November 15,

1989. The RightFax number for submission of before-final amendments is (703) 872-9306. The

RightFax number for submission of after-final amendments is (703) 872-9307.

Any inquiry concerning this communication or earlier communications from the Examiner should

be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272-0853. A message

may be left on the Examiner's voice mail system. The Examiner can normally be reached on

Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi-week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Lynette Smith can be reached on (571) 272-0864. Any inquiry of a general nature

or relating to the status of this application or proceeding should be directed to the receptionist

whose telephone number is (571) 272-1600.

Padma Baskar Ph.D.

SUPERVISORY PATENT EXAMINER

Page 5

TECHNOLOGY CENTER 1600